GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beryl Drugs Ltd (BOM:524606) » Definitions » 3-Year FCF Growth Rate

Beryl Drugs (BOM:524606) 3-Year FCF Growth Rate : 9.30% (As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Beryl Drugs 3-Year FCF Growth Rate?

Beryl Drugs's Free Cash Flow per Share for the three months ended in Mar. 2024 was ₹0.00.

During the past 12 months, Beryl Drugs's average Free Cash Flow per Share Growth Rate was -164.00% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 9.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Beryl Drugs was 148.40% per year. The lowest was -73.30% per year. And the median was 10.05% per year.


Competitive Comparison of Beryl Drugs's 3-Year FCF Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Beryl Drugs's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beryl Drugs's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beryl Drugs's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Beryl Drugs's 3-Year FCF Growth Rate falls into.



Beryl Drugs 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Beryl Drugs  (BOM:524606) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Beryl Drugs 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Beryl Drugs's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Beryl Drugs (BOM:524606) Business Description

Traded in Other Exchanges
N/A
Address
133, Kanchan Bagh, Ground Floor, Indore, MP, IND, 452001
Beryl Drugs Ltd is a pharmaceutical company principally engaged in the manufacturing and marketing of allopathic pharmaceutical preparations. It also provides contract manufacturing services and veterinary products. It offers manufacturing options for product requirements like small-volume injectables in liquid form, small-volume injectables in dry powder form, eye and ear drops, intravenous fluids in poly pack and glass bottles, and veterinary medicines. The company earns the majority of its revenue from the sale of Bulk Drugs.

Beryl Drugs (BOM:524606) Headlines

No Headlines